By Topic

3D ultrasonic molecular imaging to assess the efficacy of an aurora kinase inhibitor in pancreatic adenocarcinoma

Sign In

Cookies must be enabled to login.After enabling cookies , please use refresh or reload or ctrl+f5 on the browser for the login options.

Formats Non-Member Member
$31 $13
Learn how you can qualify for the best price for this item!
Become an IEEE Member or Subscribe to
IEEE Xplore for exclusive pricing!
close button

puzzle piece

IEEE membership options for an individual and IEEE Xplore subscriptions for an organization offer the most affordable access to essential journal articles, conference papers, standards, eBooks, and eLearning courses.

Learn more about:

IEEE membership

IEEE Xplore subscriptions

5 Author(s)

Most early phase trials use the change in tumor volume as a measure for disease response. However, it is difficult to evaluate the true efficacy of drug therapies with tumor size measurements alone. Since ultrasonic molecular imaging (MI) can provide information prior to the appearance of gross phenotypic changes, it is proposed that MI can be used to noninvasively assess early response to treatment. 10 nude mice with patient-derived tumorgrafts were used for MI experiments. 5 animals received a dose of 30 mg/kg of MLN8237 each day over a 48 hour period while the remaining animals were treated with a control vehicle. 3D MI was performed on day 0 and 48 hours after treatment using size-selected microbubble contrast agents (MCAs) fitted with a cyclic RGD peptide targeted to αvγ3, an angiogenic biomarker. At 48 hours, mean volumetric targeting decreased by 62% from baseline in treated animals compared to an 8% decrease in targeting for untreated animals (Untreated: 0.92±0.22 vs Treated: 0.38±0.23; p 0.05). Measured volume increased by 3% in treated animals as compared to a 9% increase from baseline in untreated animals (Untreated: 1.09±0.13 vs Treated: 1.03±0.03; p >; 0.05). Monitoring volumetric changes is the “gold standard” for evaluating treatment, however, our data suggests that MI may provide information about tumor response at earlier timepoints.

Published in:

Ultrasonics Symposium (IUS), 2011 IEEE International

Date of Conference:

18-21 Oct. 2011